"Despite advancements in the treatment of pediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating ...
THURSDAY, Oct. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 ...
Johnson & Johnson recently rolled out a TV ad that takes aim at a major disparity in dermatology: the fact that people of color with psoriasis are 70% less likely to be prescribed a biologic than ...
Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in clinical studies, commercials, textbooks and beyond. “The research suggests ...
Johnson & Johnson JNJ announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis drug, Tremfya, in children. Tremfya is now approved to treat pediatric and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results